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Abstract: C-5 alkynylated and N-1 alkylated pyrimidine derivatives were synthesized by N-alkylation reaction of 5-iodouracil in the presence of 
NaH, as a base, followed by Pd-catalyzed Sonogashira cross-coupling reaction of N-alkyl-5-iodouracil derivatives (1 and 2) with corresponding 
terminal alkynes. Intramolecular in situ O-heteroannulation ring closure of N-1-alkyl-C-5-alkynylpyrimidine derivatives (3 and 5) generated novel 
6-substituted furo[2,3-d]pyrimidine derivatives (7 and 8). 1,4-Disubstituted 1,2,3-triazole tethered 5-alkynylpyrimidines (14–19) and 6-substi-
tuted furo[2,3-d]pyrimidines (20–22) were successfully prepared by the copper(I)-catalyzed click reaction of 5-iodo-N-1-propargylpyrimidine 
(2) using microwave irradiation, followed by Sonogashira cross-coupling reaction with corresponding terminal alkynes. In vitro antiproliferative 
activity of prepared compounds evaluated on human cancer cell lines cervix adenocarcinoma (HeLa), colon adenocarcinoma (CaCo-2), chronic 
myeloid leukemia in blast crisis (K562), Burkitt lymphoma (Raji) revealed that pyrimidine (19) and furo[2,3-d]pyrimidine (22) derivatives with 
3,5-difluorophenyl at pyrimidine and furo[2,3-d]pyrimidine as well as p-(trifluoromethyl)phenyl at 1,2,3-triazole exhibited marked and selective 
inhibitory effects on the growth of K562 and Raji tumor cells. Antibacterial evaluations showed that pyrimidine derivative 14 substituted with 
p-tolylethynyl at C-5 of pyrimidine and benzyl at 1,2,3-triazole moiety was the most active of all evaluated compounds on the Gram positive 
bacterial strains Enterococcus faecalis. Further structure optimization of compounds 14, 19 and 22 is foreseen in order to obtain lead structural 
analogs with efficient and selective antitumoral and antibacterial activities. 
 





YRIMIDINES are essential constituents of all cells and 
thereby one of the most important heterocyclic com-
pounds.[1,2] Furthermore, pyrimidine based heterocycles 
are of interest as potential bioactive molecules and posses 
wide spectrum of biological activities such as anticancer, 
antibacterial, antifungal, antiviral, anti-inflammatory, an-
titubercular and antimalarial activity.[3–5] Modified pyrimi-
dine nucleosides were among the first chemotherapeutic 
agents to be introduced into the medical treatment of 
cancer.[6,7] In particular, a number of pyrimidine derivatives 
with potent biological properties have been prepared by 
substitution at the 5-position of the pyrimidine ring.[8,9] 
Moreover, various five-membered heteroaromatic ring-
fused pyrimidines are purinomimetics which were sub-
jected to biological investigations to assess their potential 
therapeutic usefulness such as anti-inflammatory, antibac-
terial, anticancer and antiviral agents.[10–15] Thus, furo[2,3-
d]pyrimidine attract considerable attention due to their 
great practical significance through exerting pharmaco-
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agents, and is one of the most recently explored scaffolds 
to have potential anticancer activity through inhibition of 
various protein kinases.[16–19] Besides, it was found that 
some 1,2,3-triazole tethered pyrimidine nucleosides,[20] 
1,2,3-triazole pyrimidine nucleoside conjugates with the 
1,2,3-triazole as a substituent at the pyrimidine ring,[21] the 
sugar moiety[22] or sugar mimic[23] were endowed with a 
pronounced cytostatic activity.[24] In continuation of our ef-
forts towards the hybridisation of pyrimidine and 1,2,3-
triazole scaffolds into a single chemical entity,[25] we report 
here the synthesis and biological investigations of C-5 
alkynylated pyrimidines and C-6-alkylated furo[2,3-d]pyri-
midines containing N-1-substituted 1,2,3-triazole ring. 
Moreover, the effect of substituents at pyrimidine, 
furo[2,3-d]pyrimidine and 1,2,3-triazole moieties on biolog-
ical activites was assessed. 
 
RESULTS AND DISCUSSION 
Chemistry 
The novel uracil derivatives with lateral alkynyl substituents 
at C-5 position of pyrimidine and butenyl or propargyl 
chains at position N-1 (3–6) were synthesized by the N-
alkylation reaction of 5-iodouracil with corresponding alkyl 
halide in the presence of NaH, as a base, followed by 
Sonogashira cross-coupling reaction of 5-iodouracil con-
taining 1-butenyl (1) or propargyl chain at N-1 (2) with cor-
responding terminal alkynes in the presence of Pd catalyst 
(Scheme 1). Furo[2,3-d]pyrimidine derivatives (7 and 8) 
were obtained by in situ O-heteroannulation reaction of N-
alkyl-5-alkynylpyrimidines (3 and 5) obtained in the 
Sonogashira reaction (Scheme 1). 
 1,2,3-Triazole derivatives (9–13) were synthesized 
by click reaction of the 5-iodo-N-propargyluracil derivative 
(2) with corresponding azides using microwave irradiation 
(Scheme 2). Introduction of alkynyl substituents at C-5 of 
pyrimidine ring by Sonogashira cross-coupling reaction of 
9–13 gave 5-alkynylpyrimidines (14–19) and 6-substituted 
furo[2,3-d]pyrimidines (20–22) with 1,2,3-triazole moiety 
at N-1 and N-3, respectively. 6-Substituted furo[2,3-
d]pyrimidines (20–22) were obtained by in situ 5-endo-dig 
cyclization of C-5-alkynyl-N-1-(1,2,3-triazolyl) uracil deriva-
tives (16, 17 and 19) using CuI and base (Scheme 2).  
Antiproliferative Evaluations 
Effect of pyrimidine and furo[2,3-d]pyrimidine derivatives 
of 1,2,3-triazole were investigated on the growth of human 
cervix adenocarcinoma (HeLa), colon adenocarcinoma 
(CaCo-2), chronic myeloid leukemia in blast crisis (K562), 
Burkitt lymphoma (Raji), and on the normal Madin Darby 
canine kidney (MDCK I) cells as well (Table 1). It can be ob-
served that, among all evaluated compounds, C-5-p-
tolylethynyl pyrimidine derivative 14 with benzyl moiety at 
N-1 of 1,2,3-triazole ring exhibited moderate cytostatic ef-
fect on HeLa cells. Other compounds were deprived of any 
inhibitory activities against HeLa and CaCo-2 cells. Imor-
tantly, of the 1,2,3-triazolyl-tagged pyrimidine series, com-
pounds 19 bearing 3,5-difluorophenylethynyl at C-5 of 
pyrimidine and p-(trifluoromethyl)phenyl at 1,2,3-triazole 
ring showed marked cytostatic activity (IC50 = 8.4 μM) on 
K562 cells. Furthermore, its furo[2,3-d]pyrimidine struc-
tural analog 22 exhibited also significant antitumor activity 
(IC50 = 7.9 μM) on Raji cells showing the influence of both 
3,5-difluorophenyl and p-(trifluoromethyl)phenyl substituents 
 
Scheme 1. Synthesis of N-1-alkyl (1, 2), N-1-alkyl C-5-alkynyluracil (3–6) and furo[2,3-d]pyrimidine derivatives (7, 8). Reagents 
and conditions: (i) alkylating reagent, NaH, r.t., overnight; (ii) terminal alkyne, CuI, (PPh3)4Pd, Et3N or (iso-Pr)2NH, DMF, N2 or 
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on inhibitory activities against leukemia K562 cells. Notably, 
compounds 19 and 22 were not cytotoxic to evaluated 
normal kidney (MDCK I) cells. Compound 15 displayed 
moderate antitumor effects against HeLa and CaCo-2 cells, 
while compounds 9, 18 and 20 had only marginal activity 
against these tumor cell lines (Table 1).  
Antibacterial Evaluations  
The in vitro antibacterial activity of novel pyrimidine and 
furo[2,3-d]pyrimidine derivatives was tested against 
Gram-positive bacteria including Staphylococcus aureus 
(ATCC 25923), Enterococcus faecalis, vancomycin-re-
sistant Enterococcus faecium (VRE) and Gram-negative 
bacteria including Pseudomonas aeurigonsa (ATCC 
27853), Escherichia coli (ATCC 25925), Acinetobacter 
baumannii (ATCC 19606), extended-spectrum β-lactamase 
(ESBL)-producing Klebisiella pneumoniae (Table 2). The 
obtained results were compared with known antibiotic 
ciprofloxacin (CIP). As displayed in the Table 2, almost all 
tested compounds did not show antibacterial activities on 
the growth of evaluated Gram-positive and Gram-
negative bacterial strains, except for pyrimidine deri-
vative 14 with p-tolylethynyl substituent at C-5 and benzyl 
at 1,2,3-triazole which is the most active of all evaluated 
compounds on the Gram positive bacterial strains 
Enterococcus faecalis (MIC = 8 µg/mL). 
CONCLUSIONS 
Pyrimidine derivatives containing at N-1 buteny substituent 
(3) and propargyl (4–6) side chain were synthesized by N-
alkylation reaction of 5-iodouracil followed by Pd-catalysed 
Sonogashira cross-coupling reaction of N-alkyl-5-iodouracil 
derivatives (1 and 2) with corresponding terminal alkynes. 
6-Substituted furo[2,3-d]pyrimidine derivatives (7 and 8) 
were prepared by intramolecular in situ O-hereoannulation 
ring closure of N-1-alkyl-C-5-alkynylpyrimidine derivatives 
(3 and 5). Copper(I)-catalysed click reaction of 5-iodo-N-1-
propargylpyrimidine (2) with corresponding azides fol-
lowed by Sonogashira cross-coupling reaction with termi-
nal alkynes gave novel 1,4-disubstituted 1,2,3-triazole 
tethered 5-alkynylpyrimidine (14–19) and 6-substituted 
furo[2,3-d]pyrimidines (20–22). In vitro antiproliferative 
activity of novel compounds evaluated on human cancer 
cell lines cervix adenocarcinoma (HeLa), colon adenocarci-
noma (CaCo-2), chronic myeloid leukemia in blast crisis 
(K562), Burkitt lymphoma (Raji) revealed that 3,5-difluoro-
phenyl and p-(trifluoromethyl)phenyl substituents in 
pyrimidine (19) and furo[2,3-d]pyrimidine (22) derivatives 
had strong impact on inhibitory effects on the growth of 
K562 (19, IC50 = 8.4 µM) and Raji (22, IC50 = 7.9 µM) tumor 
cells. Antibacterial evaluations showed that pyrimidine 
derivative 14 substituted with p-tolylethynyl at C-5 of  
 
Scheme 2. Synthesis of N-1-1,2,3-triazolyl (9–13), C-5-alkynyl-N-1-1,2,3-triazolyl pyrimidines (14–19), and C-6-alkyl-N-3-1,2,3-
triazolylfuro[2,3-d]pyrimidines (20–22). Reagents and conditions: (i) NaN3 or arylazide (RN3), Cu, CuSO4, H2O : t-BuOH = 1 : 1, 
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Table 1. Inhibitory effects of pyrimidine and furo[2,3-d]pyrimidine derivatives on the growth of human tumor cell lines HeLa, 
CaCo-2, Raji and K562 and normal Madin Darby canine kidney (MDCK I) cells as well. 
Compound 
IC50 / μmol dm–3 (a) 
HeLa CaCo-2 K562 Raji MDCK1 
1 > 100 > 100 > 100 > 100 > 100 
4 > 100 > 100 100 72 > 100 
5 > 100 > 100 > 100 95 > 100 
6 > 100 > 100 > 100 81 > 100 
7 > 100 > 100 100 100 100 
9 > 100 > 100 42 100 > 100 
10 > 100 > 100 100 >100 > 100 
14 37 – – 39 > 100 
15 100 > 100 13 15 > 100 
17 > 100 > 100 > 100 >100 > 100 
18 > 100 > 100 46 85 99 
19 > 100 > 100 8.4 61 > 100 
20 > 100 > 100 65 87 > 100 
21 > 100 > 100 100 >100 > 100 
22 > 100 > 100 64 7.9 > 100 
5-FUb 8.2 5.9 9.8 >100 55.1 
(a) IC50 – Compound concentration that inhibited cell growth by 50 %. Exponentially growing cells were treated with substances during 72-h period. Cytotoxicity 
was analysed using MTT survival assay. 
(b) 5-FU – 5-Fluorouracil. 
Table 2. Inhibitory effects of pyrimidine and furo[2,3-d]pyrimidine derivatives on the growth of Gram positive and Gram 
negative bacterial strains 
Compound 
MIC / µg mL–1 (a) 


















4 256 128 256 256 >256 128 >256 
5 256 128 128 256 >256 128 >256 
14 >256 8 >256 >256 >256 >256 >256 
15 >256 >256 >256 >256 >256 >256 >256 
17 >256 128 256 >256 >256 256 >256 
18 >256 128 >256 >256 >256 256 >256 
19 >256 >256 >256 >256 >256 >256 >256 
20 >256 256 256 >256 >256 256 >256 
21 >256 256 >256 >256 >256 256 >256 
22 >256 128 >256 256 >256 256 >256 
CIPd 0.125 0.5 >256 0.25 < 0.125 < 0.125 > 256 
(a) Minimal inhibitory concentration. 
(b) VRE – vancomycin-resistant Enterococcus faecium. 
(c) ESBL – extended spectrum β-lactamase = resistant strains; 
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pyrimidine and benzyl at 1,2,3-triazole is the most active of 
all evaluated compounds on the Gram positive bacterial 
strains Enterococcus faecalis (MIC 8 µg/mL). 
 Overall, compounds 19 and 22 are highlighted as 
promising candidates for further structure optimization and 
development of a new and more efficient agent for treatment 
of rapidly progressive hematological malignancies. 
 
EXPERIMENTAL 
Materials and General Methods 
Commercially available chemicals were purchased from 
Sigma Aldrich (Germany) and Acros (Belgium) and where 
used without purification. All solvents used in synthesis 
were analytical grade purity and dried. Dichloromethane 
(CH2Cl2) was stored over 4 Å molecular sieves. Methanol 
(CH3OH) and tert-buthanol (t-BuOH) were stored over 3 Å 
molecular sieves without distillation. Melting points were 
determined on a Kofler micro hot-stage instrument 
(Reichter, Wien) and were uncorrected. Precoated Merck 
silica gel 60 F254 plates were used for thin-layer chroma-
tography and spots were visualized by shortwave UV light 
(254 nm). Column chromatography was performed on 
Fluka silica gel (0.063–0.200 mm), with dichloromethane : 
methanol and dichloromethane as mobile phases. Micro-
wave-assisted syntheses were performed in a Milestone 
start S microwave oven using glass cuvettes at 80 °C and 
300W under the pressure of 1 bar. NMR spectroscopy 1H 
and 13C NMR spectra were recorded on a Varian Gemini 300 
spectrometer (Ruđer Bošković Institute, Zagreb). Samples 
were measured in DMSO-d6 solutions at 25 °C in 5 mm NMR 
tubes. 1H and 13C NMR chemical shifts (δ) in ppm were re-
ferred to TMS (δ 0.0 ppm). Individual resonances were as-
signed on the basis of their chemical shifts, signal 
intensities, multiplicity of resonances and H-H coupling 
constants. The electron impact mass spectra and the purity 
of compounds were assessed by using Agilent Technologies 
6410 Triple Quad LC/MS instrument equipped with elec-
trospray interface and triplequadrupole analyzer (LC-
MS/MS) in positive instrument mode. High performance LC 
was performed on Agilent 1100 series systemwith UV de-
tection (photodiode array detector) using Zorbax C18 
reverse-phase analytical column (2.1–30 mm, 3.5 mm). All 
compounds used for biological evaluation showed >95 % 
purity in HPLC-MS/MS system.  
Synthesis  
Compounds 2, 10–12 and 15 were prepared in accord with 
modified previously reported procedure.[25] 
 
1-(4-Bromo-2-butenyl)-5-iodopyrimidin-2,4-dione (1) 
Suspension of 5-iodouracil (5-IU) (1.02 g, 4.3 mmol) and so-
dium hydride (NaH) (98.9 mg, 4.3 mmol) in dimethyl-
formamide (DMF) (40 mL) was stirred at room temperature 
for 30 minutes. 1,4-Dibromo-2-butene was added (474.8 
mg, 3.6 mmol) to the reaction mixure and was stirred at 
room temperature overnight. Crude product mixure was 
obtained by removal of the solvent under reduced pressure 
and washed with ethyl acetate and solution of ammonium 
chloride (NH4Cl) in water. Organic layer was dried over 
MgSO4 and concentrated under reduced pressure. Crude 
product mixture was purified by silica gel column chroma-
tography (dichloromethane, then dichloromethane : meth-
anol = 30 : 1) and compound 1 (295 mg, 18.5 %) was 
isolated as yellow oil. 1H NMR (DMSO-d6): δ 11.64 (1 H, s, 
NH), 8.14 (1H, s, H-6), 5.88 (2H, dd, J = 4.7 Hz, H-2', H-3'), 
4.31 (2H, d, J = 3.8 Hz, H-4'), 4.13 (2H, dd, J = 4.3 Hz, H-1') 
ppm. 13C NMR (DMSO-d6): δ 158.82 (C-4), 149.96 (C-2), 
147.77 (C-6), 133.62 (C-2'), 126.54 (C-3'), 70.61 (C-5), 48.26 
(C-1'), 33.92 (C-4'). MS (ESI): m/z = 370.9 ([M + H]+). Anal. 
calcd. for C8H8BrIN2O2: C, 25.90; H, 2.17; N, 7.55. Found: C, 
25.81; H, 2.18; N, 7.57. 
 
A. General Procedure for Sonogashira Cross-coupling 
 Reaction 
Reaction mixture of compounds 1 or 2 with terminal alkyne 
(1.0–4.2 eq.), tetrakis(triphenylphosphine)palladium(0) 
((PPh3)4Pd) (0.1 eq.), CuI (0.2 eq.) and triethylamine (Et3N) 
or diisopropylamine ((iso-Pr)2NH) (2 eq.) in DMF (5-20 mL) 
was stirred under argon or nitrogen athmosphere at room 
temperature overnight. Removal of the solvent under re-
duced pressure obtained crude product mixure that was 
purified by silica gel column chromatography (dichloro-
methane, dichloromethane : methanol = 200 :1, 150 : 1, 
100 : 1) which resulted in isolation of products 3–8.  
 
(trans)-1-(4-bromo-2-buten-1-yl)-5-(2-(4-methylphenyl) 
ethynyl)pyrimidin-2,4-dione (3) and (trans)-3-(4-bromo-
2-buten-1-yl)-6-(4-methylphenyl)furo[2,3-d]pyrimidin-2-
one (7) 
According to procedure A, solution of compound 1 (230 mg, 
0.6 mmol), p-tolylacetylene (0.09 mL, 0.75 mmol), (PPh3)4Pd 
(87.4 mg, 0.07 mmol), CuI (28.7 mg, 0.15 mmol) and Et3N 
(0.2 mL, 1.51 mmol) in DMF (10 mL) under Ar atmosphere 
gave crude product which was purified by silica gel column 
chromatography with dichloromethane as an eluent to 
afford transparent oil of compound 3 (48 mg, 21.6 %) and 
white powder of 7 (109.2 mg, 49.1 %, m.p. 146–148 °C). 3: 
1H NMR (DMSO-d6): δ 11.66 (1H, s, NH), 8.41 (1H, s H-6), 
7.51 (4H, m, Ph), 5.75 (2H, m, H-2', H-3'), 4.80 (2H, m, H-4'), 
4.34 (2H, m, H-1'), 2.42 (3H, s, CH3-Ph) ppm. 13C NMR 
(DMSO-d6): δ 158.80 (C-4), 149.92 (C-2), 147.80 (C-6), 
136.93 (C-6''), 133.58 (C-2'), 131.76 (C-4''), 127.80 (C-5''), 
127.06 (C-3'), 119.55 (C-3''), 98.57 (C-5), 91.88 (C-2''), 85.12 
(C-1''), 48.26 (C-1'), 33.92 (C-4'), 25.11 (CH3-Ph). MS (ESI): 
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C, 56.84; H, 4.20; N, 7.80. Found: C, 57.02; H, 4.20; N, 
7.82. 7: 1H NMR (DMSO-d6): δ 8.24 (1H, s, H-4), 7.59 (4H, 
m, H-Ph), 6.36 (1H, s, H-5), 5.73 (1H, m, H-3'), 5.69 (1H, 
m, H-2'), 4.76 (2H, m, H-4'), 4.30 (2H, m, H-1'), 2.26 (3H, 
s, CH3-Ph). 13C-NMR: 191.49 (C-6), 167.88 (C-7a), 154.80 
(C-2), 136.90 (C-4''), 133.17 (C-2'), 131.79 (C-2''), 127.84 
(C-3''), 126.83 (C-3'), 126.47 (C-4), 120.03 (C-1''), 108.31 
(C-4a), 94.50 (C-5), 48.30 (C-1'), 32.87 (C-4'), 24.75 (CH3-Ph) 
ppm. MS (ESI): m/z = 359.0 ([M + H]+). Anal. calcd. for 
C17H15BrN2O2: C, 56.84; H, 4.21; N, 7.80. Found: C, 56.71; 
H, 4.20; N, 7.78. 
 
5-(Decyn-1-yl)-1-(2-propyn-1-yl)pyrimidin-2,4-dione (4) 
According to procedure A, solution of compound 2 (200 mg, 
0.72 mmol), 1-ethynyl-4-pentylbenzene (0.14 mL, 0.72 
mmol), (PPh3)4Pd (174.5 mg, 0.07 mmol), CuI (57.4 mg, 0.14 
mmol) and Et3N (0.42 mL, 1.44 mmol) in DMF (10 mL) under 
N2 atmosphere gave crude reaction product which was 
purified by silica gel column chromatography (dichloro-
methane : methanol = 150 : 1) and white powder of com-
pound 4 (100 mg, 48.4 %, m.p. > 200 °C) was isolated.  
1H NMR (DMSO-d6): δ 11.40 (1H, s, NH), 8.26 (1H, s, H-6), 
4.53 (2H, d, J = 2.5 Hz, H-1'), 3.41 (1H, t, J = 2.5 Hz, H-3'), 
2.25 (2H, t, J = 6.8 Hz, H-3"), 1.50 (2H, m, H-4''), 1.26 (10H, m, 
H-5''-H-9''), 0.72 (3H, m, C-10'') ppm. 13C NMR (DMSO-d6):  
δ 159.49 (C-4), 148.37 (C-2), 143.50 (C-6), 90.94 (C-2''), 
78.42 (C-2'), 75.52 (C-1''), 70.86 (C-3'), 98.90 (C-5), 34.22  
(C-1'), 31.48 (C-3''), 28.44, 27.69, 27.25, 27.10, 26.82 (C-4''–
C-8''), 23.07 (C-9''), 15.92 (C-10'') ppm. MS (ESI): m/z = 
287.2 ([M + H]+). Anal. calcd. for C17H22N2O2: C, 71.30; H, 
7.74; N, 9.78. Found: C, 71.12; H, 7.75; N, 9.81. 
 
5-(Dodecyn-1-yl)-1-(2-propyn-1-yl)pyrimidin-2,4-dione (5) 
and 6-decyl-3-(2-propyn-1-yl)furo[2,3-d]pirimidine (8) 
According to procedure A, solution of compound 2 (170 mg, 
0.6 mmol), dodec-1-yne (0.2 mL, 0.9 mmol), (PPh3)4Pd (70.8 
mg, 0.6 mmol), CuI (23.3 mg, 0.12 mmol) and (iso-Pr)2NH 
(0.2 mL, 1.2 mmol) in DMF (20 mL) gave crude reaction 
product that was purified by silica gel column chromatog-
raphy (dichloromethane, dichloromethane : methanol =  
100 : 1) which gave white crystals of compound 5 (23.2 mg, 
12.1 %; m.p. 123–125 °C) and yellow oil of compound 8  
(9.6 mg, 5 %). 5: 1H NMR (DMSO-d6): δ 11.64 (1H, s, NH), 
7.97 (1H, s, H-6), 4.65 (2H, s, H-1'), 3.41 (1H, s, H-3'), 2.36 
(2H, t, J = 6.8 Hz, H-3''), 1.46 (2H, p, J = 7.2 Hz, H-4''), 1.37 
(2H, m, H-5''), 1.29–1.21 (12H, m, H-6''-H-14''), 0.85 (3H, t, 
J = 6.3 Hz) ppm. 13C NMR (DMSO-d6): δ 161.28 (C-4), 149.50 
(C-2), 144.36 (C-6), 91.34 (C-2''), 79.40 (C-2'), 74.01 (C-1''), 
70.85 (C-3'), 98.97 (C-5), 34.20 (C-1'), 30.17 (C-3''), 29.56, 
28.44, 28.40, 27.70, 27.28, 26.95, 26.43 (C-4''–C-10''), 23.10 
(C-11''), 16.84 (C-12'') ppm. MS (ESI): m/z = 315.2 ([M + H]+). 
Anal. calcd. for C19H26N2O2: C, 72.58; H, 8.33; N, 8.91. 
Found: C, 72.38; H, 8.34; N, 8.90. 8: 1H NMR (DMSO-d6):  
δ 8.49 (1H, s, H-4), 5.87 (1H, s, H-5), 4.32 (2H, s, J = 6.4 Hz, 
H-1'), 3.62 (1H, t, J = 6.7 Hz, H-3'), 2.64 (2H, t, J = 7.2 Hz,  
H-1''), 2,17 (2H, m, H-2''), 1.84-1.45 (10H, m, H-3''-H-7''), 
0.86 (3H, t, J = 7.2 Hz, CH3) ppm. MS (ESI): m/z = 315.2 ([M 
+ H]+). Anal. calcd. for C19H26N2O2: C, 72.58; H, 8.33; N, 8.91. 




According to procedure A, solution of 2 (170 mg, 0.6 mmol), 
1-ethynyl-4-pentylbenzene (0.17 mL, 0.9 mmol), (PPh3)4Pd 
(70.8 mg, 0.6 mmol), CuI (23.3 mg, 0.12 mmol) and (iso-
Pr)2NH (0.2 mL, 1.2 mmol) in DMF (20 mL) gave crude reac-
tion product that was purified by silica gel column chroma-
tography (dichloromethane, dichloromethane : methanol = 
200 : 1) which gave yellow crystals of compound 6 (128.1 
mg, 65.4 %, m.p. 154–155 °C). 1H NMR (DMSO-d6): δ 11.24 
(1H, s, NH), 7.92 (1H, s, H-6), 7.28 (2H, d, J = 8.3 Hz, Ph), 7.14 
( 2H, d, J = 8.2 Hz, Ph), 4.54 (2H, d, J = 2.6 Hz, H-1'), 3.41 (1H, 
t, J = 2.6 Hz, H-3'), 2.34 (2H, t, J = 7.1 Hz, H-1''), 1.48 (2H, 
pent, J = 6.8 Hz, H-2''), 1.36 (2H, m, H-4''), 1.30 (2H, m,  
H-3''), 0.87 (3H, t, J = 7.0 Hz, H-5'') ppm. 13C NMR (DMSO-d6): 
δ 163.18 (C-4), 150.27 (C-2), 145.73 (C-6), 81.15 (C-2'), 
71.13 (C-3'), 92.28 (C-5), 33.48 (C-1'). MS (ESI): m/z = 321.2 
([M + H+]). Anal. calcd. for C20H20N2O2: C, 74.98; H, 6.29;  
N, 8.74. Found C, 75.19; H, 6.28; N, 8.73. 
 
B. General Procedure for Introduction of  
 1,2,3-Triazolyl Substituent by Click Reaction  
Reaction mixture of compound 2 (1.0 eq.), alkyl/aryl azide 
(RN3) (1.1–1.9 eq.), copper (Cu (0)) (1.0–1.4 eq), solution of 
copper-sulphate (CuSO4, 1M) (0.1 mL), solution of tert-butan-
ole and water in 1 : 1 ratio (t-BuOH : H2O = 1 : 1) (10 mL) and 
dimethylformamide (DMF) (7 mL) was stirred in microwave 
reactor at 80 °C and 300 W for 30-45 minutes. Crude 
product mixure was obtained by removal of the solvent 
under reduced pressure and was purified by silica gel 
column chromatography (dichloromethane:methanol =50:1 
or 30 : 1) and products 9–13 were obtained.  
 
5-Iodo-1-(1,2,3-triazol-4-yl)methyl)pyrimidin-2,4-dione (9) 
According to procedure B, solution of compound 2 (100 mg, 
0.37 mmol), sodium azide (NaN3) (28.8 mg, 0.44 mmol), Cu 
(0) (22.8 mg, 0.37 mmol), CuSO4 (0.1 mL) and t-BuOH :H2O= 
1:1 (10 mL) after evaporation of solvents gave crude 
product mixture that was purified by silica gel column chro-
matography (dichloromethane :methanol =30:1) and gave 
white crystals of compound 9 (20.2 mg, 16.9 %, m.p. 185–
186 °C). 1H NMR (DMSO-d6): δ 11.74 (1H, s, NH), 8.64 (1H, 
s, H-3'), 8.23 (1H, s, NH), 8.10 (1H, s, H-6), 4.49 (2H, d,  
J = 2.7 Hz, H-1') ppm. 13C-NMR (DMSO-d6): δ 162.06 (C-4), 
151.11 (C-2), 149.20 (C-6), 143.77 (C-2'), 121.49 (C-3'), 
68.51 (C-5), 43.21 (C-1') ppm. MS (ESI): m/z = 319.9 ([M + 
H]+). Anal. calcd. for C7H6IN5O2: C, 26.35; H, 1.90; N, 21.95. 
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According to procedure B, solution of compound 2 (200 mg, 
0.73 mmol), 1-azido-4-(trifluoromethyl)benzene (1.74 mL, 
0.78 mmol), Cu (0) (46.6 mg, 0.73 mmol), 1M CuSO4 (0.1 
mL), t-BuOH : H2O = 1 : 1 (10 mL) and DMF (7 mL) after 
evaporation of solvents gave crude product mixture that 
was purified by silica gel column chromatography (dichloro-
methane : methanol = 50 : 1) and gave white crystals of 
compound 13 (195.8 mg, 57.8 % , m.p. 256-258°C). 1H NMR 
(DMSO-d6): δ 11.72 (1H, s, NH), 8.94 (1H, s, H-3'), 8.36 (1H, 
s, H-6), 8.16 (2H, d, J = 8.5 Hz, H-5'-Ph), 7.99 (2H, d, J = 8.6 
Hz, H-4'-Ph), 5.07 (2H, s, H-1') ppm. 13C-NMR (DMSO-d6):  
δ 161.60 (C-4), 151.89 (C-2), 150.43 (C-7', q, J = 20.2 Hz,  
C-F), 150.22 (C-6), 144.17 (C-2'), 128.65 (C-4'), 123.76 (CF3, 
q, J = 254.2 Hz, C-F), 123.07 (C-5', q, J = 2.6 Hz, C-F), 122.54 
(C-3'), 119.28 (C-6', q, J = 8.4 Hz, C-F), 70.82 (C-5), 43.25  
(C-1') ppm. MS (ESI): m/z = 464.2 ([M + H]+). Anal. calcd. for: 
C14H9F3IN5O2. C, 36.31; H, 1.96; N, 15.12. Found: C, 36.28; 




 According to procedure A solution of compound 10 
(17.8 mg, 0.06 mmol), p-tolylacetylene (34 μL, 0.06 mmol), 
Cu (0) (3.6 mg, 0.03 mmol), 1M CuSO4 (12 µL), t-BuOH : H2O = 
1 : 1 (1 mL) and DMF (1 mL) after evaporation of solvents 
gave crude product mixture that was purified by silica gel 
column chromatography (dichloromethane) and gave yellow 
crystals of compound 14 (15.1 mg, 63.4 %; m.p. 81–83 °C). 1H 
NMR (DMSO-d6): δ 11.63 (1H, s, NH), 8.77 (1H, s, H-6), 7.97 
(1H, s, H-3'), 7.61–7.37 (9H, m, Ph), 5.08 (2H, s, CH2-Ph), 
4.61 (2H, s, H-1'), 1.85 (3H, s, CH3) ppm. 13C-NMR (DMSO-
d6): δ 161.58 (C-4), 152.14 (C-2), 150.09 (C-6), 142.50 (C-2'), 
138.52 (C-6''),136.11 (C-5'), 131.79 (C-4''), 130.18 (C-5''), 
128.73 (C-6'), 128.36 (C-8'), 127.71 (C-7'), 123.73 (C-3'), 
120.26 (C-3''), 93.94 (C-5), 92.66 (C-2''), 75.28 (C-1''), 54.24 
(C-4'), 42.73 (C-1'), 23.12 (CH3) ppm. MS (ESI): m/z = 397.2 
[M+H+]). Anal. calcd. for C23H19N5O2: C, 69.51; H, 4.82;  
N, 17.62. Found C, 69.45; H, 4.81; N, 17.64. 
 
5-(Dodecyn-1-yl)-1-(1-(4-fluorophenyl)-1,2,3-triazol-4-yl) 
methyl)pyrimidine-2,4-dione (16) and 6-(dec-1-yl)-3-(1-
(4-fluorophenyl)-1,2,3-triazol-4-yl)methyl)furo[2,3-d] 
pyrimidine (20) 
According to procedure A, solution of compound 11 (30 mg, 
0.07 mmol), dodec-1-yne (0.03 mL, 0.15 mmol), (PPh3)4Pd 
(8.3 mg, 0.007 mmol), CuI (2.7 mg, 0.015 mmol) and (iso-
Pr)2NH (3 μL, 0.24 mmol) in DMF (5 mL) gave crude reaction 
product that was purified by silica gel column chromatog-
raphy (dichloromethane, dichloromethane : methanol =  
100 : 1) which resulted in isolation of yellow oil of compound 
16 (11.2 mg, 35.4 %) and yellow crystals of compound 20 
(17.3 mg, 54.7 %, m.p. 209–210 °C). 16: 1H NMR (DMSO-d6): 
δ 11.72 (1H, s, NH), 8.41 (1H, s, H-6), 8.06 (1H, s, H-3'), 7.46 
(2H, d, J = 8.1 Hz, Ph), 7.37 (2H, d, J = 8.1 Hz, Ph), 4.71 (2H, 
s, H-1'), 2.43 (2H, t, J = 7.1 Hz, H-3''), 1.58 (2H, m, H-4''), 1.41 
(2H, m, H-5''), 1.18-1.27 (12H, m, H-6''-H-11''), 0.87 (3H, t, J 
= 6.5 Hz) ppm. 13C-NMR (DMSO-d6): δ 162.38 (C-4), 159.28 
(C-7'), 150.14 (C-2),147.53 (C-6), 143.86 (C-2'), 133.58  
(C-4'), 122.80 (C-5'), 121.69 (C-3'), 118.44 (C-6'), 98.57  
(C-5), 93.31 (C-2''), 72.68 (C-1''), 31.25 (C-8''), 28.63, 28.51, 
28.23, 27.66, 26.53, 25.49, (C4''–C10''), 22.14 (C-11''), 18.79 
(C-3''), 13.95 (CH3) ppm. MS (ESI): m/z = 452.2 ([M + H+]). 
Anal. calcd. for C25H30FN5O2: C, 66.50; H, 6.70; N, 15.51. 
Found C, 66.56; H, 6.71; N, 15.49. 20: 1H NMR (DMSO-d6):  
δ 8.64 (1H, s, H-4), 8.05 (1H, s, H-3'), 7.43 (2H, t, J = 5.5 Hz, 
Ph), 7.21 (2H, d, J = 5.8 Hz, Ph), 6.56 (1H, s, H-5), 4.78 (2H, 
s, H-1'), 3.60 (2H, t, J = 6.9 Hz, H-1''), 2.26 (2H, m, H-2''), 1.74 
‒ 1.38 (10H, m, H-3''– H-9''), 0.87 (t, J = 7.1 Hz, CH3) ppm. 
13C-NMR (DMSO-d6): δ 168.46 (C-6), 162.13 (C-7'), 160.94 
(C-7a), 155.07 (C-2), 144.15 (C-2'), 143.36 (C-4), 133.52 (C-
4'), 122.78 (C-5'), 122.43 (C-3'), 117.26 (C-6'), 107.16 (C-4a), 
100.65 (C-5), 46.18 (C-1'), 45.34 (C-1''), 30.04 (C-2''), 28.56, 
28.16, 27.64, 26.55, 25.47, 25.23, 24.74 (C3''–C9''), 13.88 
(CH3) ppm. MS (ESI): m/z = 452.2 ([M + H+]). Anal. calcd. for 
C25H30FN5O2: C, 66.50; H, 6.70; N, 15.51. Found C, 66.44; H, 
6.69; N, 15.49. 
 
1-((1-(4-Chlorophenyl)-1,2,3-triazol-4-yl)methyl)-5-(4-(tolyl) 
ethynyl)pyrimidin-2,4-dione (17) and 3-((1-(4-chlorophenyl)-
1,2,3-triazol-4-yl)methyl)-6-tolylfuro[2,3-d]pyrimidine (21) 
According to procedure A, solution of compound 12 (30 mg, 
0.07 mmol), p-tolylacetylene (13 μL, 0.1 mmol), (PPh3)4Pd 
(8 mg, 0.007 mmol), CuI (2.6 mg, 0.014 mmol) and Et3N (19 
μl, 0.14 mmol) in DMF (5 mL) gave crude reaction product 
that was purified by silica gel column chromatography 
(dichloromethane, dichloromethane : methanol = 100 : 1) 
which resulted in isolation of yellow oil of compound 17 
(15.1 mg, 51.5 %) and yellow oil of compound 21 (12 mg, 
40.9 %). 17: 1H NMR (DMSO-d6): δ 11.80 (1H, s, NH), 8.25 
(1H, s, H-6), 7.91 (1H, s, H-3'), 7.41 (2H, dd, J = 29.8, 8.1 Hz, 
Ph), 7.35–7.21 (6H, m, Ph), 4.77 (2H, s, H-1'), 2.33 (3H, s, 
CH3-Ph) ppm. 13C-NMR (DMSO-d6): δ 162.26 (C-4), 157.44 
(C-7'), 149.48 (C-2), 147.50 (C-6), 144.17 (C-2'), 138.43  
(C-6''),133.62 (C-4'), 131.24 (C-4''), 129.40 (C-5''),123.08  
(C-5'), 121.70 (C-3'), 120.35 (C-6'), 119.44 (C-3''), 97.62  
(C-5), 93.40 (C-2''), 73.17 (C-1''), 21.56 (CH3) ppm. MS (ESI): 
m/z = 418.1 ([M + H+]). Anal. calcd. for C22H16ClN5O2:  
C, 63.24; H, 3.86; N, 16.76. Found C, 63.33; H, 3.87;  
N, 16.74. 21: 1H NMR (DMSO-d6): δ 8.54 (1H, s, H-4), 8.05 
(1H, s, H-3'), 7.37-7.19 (8H, m, Ph), 6.43 (1H, s, H-5), 4.46 
(2H, s, H-1'), 2.31 (3H, s, CH3) ppm. 13C-NMR (DMSO-d6):  
δ 169.25 (C-6), 162.30 (C-7'), 160.81 (C-7a), 154.54 (C-2), 
143.88 (C-2'), 143.30 (C-4), 141.15 (C-4''),133.49 (C-4'), 
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120.37 (C-1''), 118.34 (C-6'), 107.55 (C-4a), 98.43 (C-5), 46.40 
(C-1'), 19.96 (CH3) ppm. MS (ESI): m/z = 417.8 ([M + H+]). Anal. 
calcd. for C22H16ClN5O2: C, 63.24; H, 3.86; N, 16.76. Found  




According to procedure A, solution of compound 13 (30 mg, 
0.06 mmol), p-tolylacetylene (0.03 mL, 0.25 mmol), 
(PPh3)4Pd (7.4 mg, 0.006 mmol), CuI (2.4 mg, 0.012 mmol) 
and Et3N (0.02 mL, 0.12 mmol) in DMF (2 mL) gave crude 
reaction product that was purified by silica gel column chro-
matography (dichloromethane) which resulted in isolation 
of yellow oil of compound 18 (13.3 mg, 49.1 %). 1H NMR 
(DMSO-d6): δ 11.74 (1H, s, NH), 8.98 (1H, s, H-3'), 8.33 (1H, 
s, H-6), 8,17 (1H, d, J =8.4 Hz, H-5'-Ph), 7.99 (1H, d, J = 8.5 
Hz, H-5'-Ph), 7.63-7.54 (4H, m, H-1'', H-2''), 7.36 (1H, d,  
J = 8.5 Hz, H-4'-Ph), 7.22 (1H, d, J =7.9 Hz, H-4'-Ph), 5.12 (2H, 
s, H-1'), 2.33 (3H, s, CH3) ppm. 13C-NMR (DMSO-d6): 162.49 
(C-4), 151.87 (C-2), 150.58 (C-7', q, J = 24.1 Hz, C-F), 149.64 
(C-6), 141.73 (C-2'), 138.50 (C-6''), 132.01 (C-4''), 128.65  
(C-4'), 128.40 (C-5''), 123.97 (C-5', q, J = 2.3 Hz, C-F), 123.85 
(CF3, q, J = 251.8 Hz, C-F), 123.72 (C-3'), 120.41 (C-3''), 
119.44 (C-6', q, J = 8.1 Hz, C-F), 94.48 (C-5), 93.17 (C-2''), 
75.26 (C-1''), 48.38 (C-1'), 23.10 (CH3) ppm. MS (ESI): m/z = 
452.4 ([M + H+]). Anal. calcd. for C23H16F3N5O2: C, 61.20;  




(19) and 6-(3,5-difluorophenyl)-3-((1-(4-(trifluoromethyl) 
phenyl)-1,2,3-triazol-4-yl)methyl)furo[2,3-d]pyrimidin-2-
one (22)  
According to procedure A, solution of compound 13 (120 mg, 
0.26 mmol), 1-ethynyl-3,5-difluorobenzene (0.05 mL, 0.39 
mmol), (PPh3)4Pd (29.7 mg, 0.03 mmol), CuI (9.8 mg, 0.05 
mmol) and Et3N (0.07 mL, 0.52 mmol) in DMF (8 mL) gave 
crude reaction product that was purified by silica gel 
column chromatography (dichloromethane) which resulted in 
isolation of white crystals of compound 19 (32.6 mg, 26.4 %, 
m.p. > 260 °C) and yellow crystals of compound 22 (42.8 mg, 
34.7 %, m.p. 88–90 °C). 19: 1H NMR (DMSO-d6): δ 11.38 (1H, 
s, NH), 8.99 (1H, s, H-3'), 8.42 (1H, s, H-4), 8.17 (2H, d,  
J = 8.5 Hz, H-5'-Ph), 7.99 (2H, d, J = 8.6 Hz, H-4'-Ph), 7.35 
(1H, m, H-2''), 7.22 (2H, d, J = 5.9 Hz, H-1''), 5.07 (2H, s,  
H-1') ppm. 13C-NMR (DMSO-d6): 161.33 (C-4), 154.87 (C-5'', 
d, J = 248.7 Hz, C-F), 150.94 (C-2), 148.56 (C-6), 143.21  
(C-2'), 133.74 (C-7', q, J = 18.7 Hz, C-F), 132.44 (C-5'), 132.01 
(C-4'), 127.60 (C-3''), 126.47 (C-6', q, J = 9.3 Hz, C-F), 123.85 
(CF3, q, J = 250.6 Hz, C-F), 123.74 (C-3'), 118.12 (C-4'', d,  
J = 25.2 Hz, C-F), 103.83 (C-6'', t, J = 31.1 Hz, C-F), 98.67  
(C-5), 93.58 (C-2''), 81.42 (C-1''), 48.47 (C-1') ppm. MS (ESI): 
m/z = 474.1 ([M + H+]). 22: 1H NMR (DMSO-d6): δ 8.94 (1H, 
s, H-3'), 8.37 (1H, s, H-4), 8.16 (2H, d, J = 9.0 Hz, H-6'), 7.99 
(2H, d, J = 8.5 Hz, H-5'), 7.65-7.57 (3H, m, H-1'', H-2''), 6.26 
(1H, s, H-5), 5.07 (2H, s, H-1') ppm. 13C-NMR (DMSO-d6):  
δ 172.26 (C-6), 166.38 (C-7a), 163.12 (C-3'', d, J = 249.6 Hz, 
C-F), 156.87 (C-2), 144.54 (C-2'), 141.82 (C-4), 132.55 (C-1'', 
d, J = 7.8 Hz, C-F), 132.01 (C-4'), 131.19 (C-7', q, J = 23.2 Hz, 
C-F), 129.64 (C-5', q, J = 2.4 Hz, C-F), 127.88 (CF3, q, J = 243.7 
Hz, C-F), 124.53 (C-6', q, J = 8.6 Hz, C-F), 118.47 (C-3'), 
110.25 (C-4'', t, J = 26.7 Hz, C-F), 107.86 (C-2'', d, J = 26.7 Hz, 
C-F), 106.23 (C-4a), 92.57 (C-5), 46.28 (C-1') ppm. MS (ESI): 
m/z = 474.4 ([M + H+]). Anal. calcd. for C22H12F5N5O2:  
C, 55.82; H, 2.56; N, 14.80. Found C, 55.94; H, 2.57; N, 14.78. 
Biological Evaluations  
Cell Cultured 
Cells were cultured in tissue culture flasks (25, 75 cm2) in 
humidified atmosphere under the conditions of 37 °C / 5 % 
of CO2 gas in the CO2 incubator (IGO 150 CELLlifeTM, JOUAN, 
Thermo Fisher Scientific, Waltham, MA, USA). HeLa, CaCo-2 
and MDCK I were maintained in DMEM medium comple-
mented with 10 % heat-inactivated FBS, 2 mM glutamine, 
and 100U / 0.1 mg penicillin / streptomycin. Cell lines in 
suspension, K562 and Raji, were cultured in RPMI-1640 me-
dium complemented with 10 % heat-inactivated FBS, 2 mM 
glutamine, 1 mM Na-pyruvate, and 10 mM HEPES. Cell 
viability was assessed by the trypan blue dye exclusion 
method before each experiment. 
 
Cytotoxicity Evaluation 
Cytotoxic effects on the tumors cell growth were deter-
mined using the colorimetric methyltetrazolium (MTT) as-
say. Experiments were carried out on four tumor human 
cell lines (HeLa, CaCo-2, K562 and Raji) and on one canine 
cell line (MDCK I) as normal cells. The adherent cells were 
seeded in 96 micro-well plates at a concentration of 2 × 104 
cells/mL and allowed to attach wall plate overnight in the 
CO2 incubator. After 72 hours of incubation with tested 
compounds, the medium was replaced with 5 mg/mL MTT 
solution and the resulting formazane crystals were dis-
solved in DMSO. Suspension cells (K562 and Raji) at a con-
centration of 1×105 cells/mL, were plated onto 96 micro-
well plates and the same day were treated with tested ex-
tracts at different concentrations. After expired 72 hours of 
incubation, 5mg/mL MTT solution was added to each well 
and incubated 4 hours in CO2 incubator. To each well, 10 % 
SDS with 0.01 mol/L HCl was added to dissolve water-insol-
uble MTT-formazane crystals overnight. Elisa micro plate 
reader (iMark, BIO RAD, Hercules, CA, USA) was used for 
measurement of absorbance at 595 nm. 
 All experiments were performed at least three times 
in triplicates. The percentage of cell growth (PG) was 
calculated using the following equation 
 = ×compound background
control background
–
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where Abackground at the adherent cells is absorbance of MTT 
solution and DMSO; Abackground at cells growing in suspen-
sion is absorbance of the medium without cells, but con-
taining MTT and 10 % SDS and 0.01 mol/L HCl; and Acontrol is 
the absorbance of cell suspension grown without tested 
compounds. 
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